Researchers have discovered how a cancer-linked version of the protein mitoNEET can close voltage-dependent anion channels (VDAC), primary gateways in the outer surface of mitochondria. The researchers detail how mitoNEET regulates VDAC, and they show that the interactions between the two proteins could be disrupted by a drug that targets VDAC.